Clinical trials: Lymphoid Leukemia, Acute
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01116154
- Testing
- lenalidomide, vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02037256
- Testing
- bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hematologic Malignancies, Leukemia
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Primary objective: To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of TCN-PM (Triciribine) when administered as an approximately one-hour intravenous infusion on a weekly schedule on days 1, 8 and…
- Trial name
- NCT00642031
- Testing
- Triciribine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Prescient Therapeutics, Ltd.
B Cell Lymphoma, Acute Lymphoblastic Leukemia
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
1. Study Title: A Study on the Efficacy and safety of Autocrine p40-Expressing CD19-Targeted Chimeric Antigen Receptor T Cells (CD19-CAR.p40-T) in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies 2.
- Conditions
- B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- CAR-p40-T (NCT07584889)
- Testing
- CAR-T cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02269579
- Testing
- CPX-351
- Where
- 5 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Acute Lymphoblastic Leukemia
The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia
The Guangdong work group of childhood acute lymphoblastic leukemia (ALL) therapy was set up in October 2002. The investigators treated the childhood ALL with a GZ2002 protocol since the year 2002, and the protocol was mainly…
- Trial name
- NCT00846703
- Testing
- 6-mercaptopurine, Methotrexate, 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients after reduced-intensity conditioning and stem cell transplant.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03267186
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Andrew Rezvani
Acute Lymphoblastic Leukemia
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
This is a Phase I, single-center, open label, prospective, single-arm, dose-escalation and multi-dose study evaluating the use of ibrutinib in combination with dasatinib and prednisone therapy.
- Trial name
- NCT02815059
- Testing
- Ibrutinib, Dasatinib, Prednisone
- Where
- United States
- Sponsor
- University of Utah
Leukemia, Acute Lymphoblastic Leukemia
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
This is a pilot study of a drug called rituximab used together with other drugs-prednisone, etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of standard chemotherapy for relapsed Acute…
- Conditions
- Leukemia, Acute Lymphoblastic Leukemia, ALL
- Trial name
- Rituximab (NCT01230788)
- Testing
- rituximab
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Acute Lymphoblastic Leukemia
Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia
The goal of this observational study is to quantify the burden of particularly severe, long-term adverse effects in childhood acute lymphoblastic leukemia (ALL) survivors.
- Trial name
- NCT05639673
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Leukemia, Metabolic Syndrome X
Adipokines as Predictors of the Metabolic Syndrome in ALL Survivors
Background: Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for 25% of all childhood cancers. Peak incidence occurs between 2 to 5 years of age.
- Trial name
- NCT00566566
- Testing
- sample without DNA
- Volunteers
- 150 people
- Sponsor
- Sheba Medical Center
Leukemia, Lymphoma
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant helps stop both the growth of cancer cells and the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00301951
- Testing
- anti-thymocyte globulin, sargramostim, busulfan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
This phase II trial studies how well an umbilical cord blood transplant with added sugar works with chemotherapy and radiation therapy in treating patients with leukemia or lymphoma.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03096782
- Testing
- Anti-Thymocyte Globulin, Busulfan, Clofarabine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
A common and potentially debilitating late effect of childhood cancer treatment is neurocognitive impairment, frequently in the domain of executive dysfunction, which can limit educational attainment, employment, and quality of…
- Trial name
- NCT02336282
- Testing
- transcranial Direct Current Stimulation (tDCS), Cognitive Assessment, Brain Games Stimulation
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphoma
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Giving high doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00521261
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
This is a Phase I trial to assess the safety and feasibility of administering pre-manufactured allogeneic T cells from healthy donors expressing CD19-targeting chimeric antigen receptors lacking expression of HLA class I, HLA…
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT05037669
- Testing
- PACE CART19
- Sponsor
- University of Pennsylvania
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
- Trial name
- NCT03185494
- Testing
- anti-CD19/22-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00598169
- Testing
- rituximab, bortezomib, carboplatin
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- AIDS Malignancy Consortium
Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
With this research study has following goals To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated.
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04996160
- Testing
- Palbociclib, Dexamethasone, Bortezomib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tanja Andrea Gruber